Difficulty: Medium
Average Score: 82%
Practice
For the child with hypoplastic left heart syndrome, which medication may be given to keep the patent ductus arteriosus (PDA) open until surgery can be done?
Correct answer
A
Rationale
In the context of pediatric cardiovascular nursing, understanding the management of congenital heart defects like hypoplastic left heart syndrome is crucial. The correct answer to the question is A) Prostaglandin E. Prostaglandin E is given to keep the patent ductus arteriosus (PDA) open in infants with critical congenital heart defects, including hypoplastic left heart syndrome, to maintain pulmonary or systemic blood flow until surgical intervention can be performed.
Indomethacin and ibuprofen, options B and C, are nonsteroidal anti-inflammatory drugs (NSAIDs) that are used to close a PDA by inhibiting prostaglandin synthesis. Therefore, they would be contraindicated in this scenario when we want to keep the PDA open.
Digoxin, option D, is a medication commonly used in pediatric cardiology to treat heart failure by improving cardiac contractility. However, it is not the appropriate choice for keeping the PDA open in hypoplastic left heart syndrome.
Educationally, it is essential for pediatric nurses to understand the rationale behind using specific medications in pediatric cardiovascular conditions to provide safe and effective care to this vulnerable population. Recognizing the pharmacological management of congenital heart defects and the medications involved is crucial for optimizing patient outcomes and preparing for potential complications.
Indomethacin and ibuprofen, options B and C, are nonsteroidal anti-inflammatory drugs (NSAIDs) that are used to close a PDA by inhibiting prostaglandin synthesis. Therefore, they would be contraindicated in this scenario when we want to keep the PDA open.
Digoxin, option D, is a medication commonly used in pediatric cardiology to treat heart failure by improving cardiac contractility. However, it is not the appropriate choice for keeping the PDA open in hypoplastic left heart syndrome.
Educationally, it is essential for pediatric nurses to understand the rationale behind using specific medications in pediatric cardiovascular conditions to provide safe and effective care to this vulnerable population. Recognizing the pharmacological management of congenital heart defects and the medications involved is crucial for optimizing patient outcomes and preparing for potential complications.